Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related Conditions
13 Mayo 2024 - 8:00AM
Beacon Biosignals announced a strategic partnership with Longboard
Pharmaceuticals, Inc. that combines Longboard’s drug development
expertise with Beacon’s neurophysiological platform to develop a
better understanding of the relationship between sleep and
neurological conditions with an initial focus in rare epileptic
syndromes.
“We spend a third of our lives sleeping, yet
sleep has received little attention when assessing the patient
profile in many neurological conditions. As a result, clinical
development of therapies that impact the brain have historically
ignored the critical physiology of sleep when assessing patient
outcomes and treatment effectiveness,” said Jacob Donoghue, MD,
PhD, CEO of Beacon Biosignals. “Our partnership with Longboard
changes all of that. We’re excited to collaborate in studying the
utility of sleep and factors that may impact the management of
neurological conditions, particularly in rare epilepsies.”
The Beacon Platform offers unparalleled tools to
derive new insights for drug development and research. Initially,
this collaboration will deploy Beacon’s FDA-cleared Dreem 3S™ EEG
headband device and AI algorithm-derived neurobiomarkers to
interrogate the neurophysiology of sleep longitudinally, at-scale,
and from the comfort of a person’s home. This collaboration thereby
enables Longboard to collect laboratory-quality sleep data while
reducing the burden on patients and caregivers.
“Longboard is excited to partner with Beacon
with the goal of pioneering a new era of research by leveraging
innovative biomarker insights, approaches, and technology. Our hope
is to apply data and key learnings obtained from our combined
experience in clinical studies and EEG analyses to ultimately
improve outcomes for patients and their families,” stated Dr.
Randall Kaye, Longboard’s Chief Medical Officer. Dr. Kaye added,
“our partnership with Beacon will help us in our mission to
transform the lives of patients with neurological and rare
diseases.”
About Beacon
Biosignals
Beacon Biosignals is the leading at-home EEG
platform for precision drug development. Its FDA 510(k)-cleared
Dreem 3 EEG headband and FDA-cleared algorithms enable and
accelerate research and development of treatments that transform
the lives of patients with neurological, psychiatric, and sleep
disorders. Beacon’s Clinico-EEG database contains over 100,000
patients’ brain activity data, and its cloud-native analytics
platform empowers rapid interrogation of RWD/RWE for retrospective
and predictive studies. For more information, visit
https://beacon.bio. Follow us on Twitter or LinkedIn.
Beacon Biosignals media contact: info@beacon.bio